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Abstract
Background: The b-amyloid peptide (Ab) contains a Gly-XXX-Gly-XXX-Gly motif in its C-terminal region that has
been proposed to form a “glycine zipper” that drives the formation of toxic Ab oligomers. We have tested this
hypothesis by examining the toxicity of Ab variants containing substitutions in this motif using a neuronal cell line,
primary neurons, and a transgenic C. elegans model.
Results: We found that a Gly37Leu substitution dramatically reduced Ab toxicity in all models tested, as measured
by cell dysfunction, cell death, synaptic alteration, or tau phosphorylation. We also demonstrated in multiple
models that Ab Gly37Leu is actually anti-toxic, thereby supporting the hypothesis that interference with glycine
zipper formation blocks assembly of toxic Ab oligomers. To test this model rigorously, we engineered second site
substitutions in Ab predicted by the glycine zipper model to compensate for the Gly37Leu substitution and
expressed these in C. elegans. We show that these second site substitutions restore in vivo Abtoxicity, further
supporting the glycine zipper model.
Conclusions: Our structure/function studies support the view that the glycine zipper motif present in the C-
terminal portion of Ab plays an important role in the formation of toxic Ab oligomers. Compounds designed to
interfere specifically with formation of the glycine zipper could have therapeutic potential.
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Background
Many studies support the view that accumulation of the
b-amyloid peptide (Ab) is central to Alzheimer’sd i s e a s e
pathology [1]. Synthetic Ab is toxic in both neuronal
cell lines [2,3] and primary neurons [4], and Alzhei-
mer’s-like pathology has been observed in a range of
transgenic models that accumulate Ab [5-8]. Although
numerous studies have implicated oligomeric Ab as the
toxic species [9-11], the structure of the key toxic Ab
species is unresolved, as is the toxic mechanism. As it
has not been possible to obtain atomic structures for Ab
by X-ray crystallography, there is significant disagree-
ment as to whether the toxic form of Ab involves an a-
helical or b-sheet structure.
Synthetic Ab preparations can convincingly form
pores in synthetic membranes, leading to the proposal
that in vivo Ab toxicity results specifically from direct
membrane damage [12]. Interestingly, the hydrophobic
C-terminal region of Ab (corresponding to the trans-
membrane portion of the amyloid precursor protein,
APP) contains a Gly-XXX-Gly-XXX-Gly motif, termed a
“glycine zipper” by Kim et al [13]. These researchers
pointed out that this motif is present in the transmem-
brane domains of a number of bacterial channel pro-
teins, and structural modeling of these channel proteins
suggests that the glycine zipper motif can drive the
packing of transmembrane a-helices. A schematic
model showing the potential glycine zipper motif inter-
face between a-helical regions of two Ab peptides is
shown in Figure 1. To support the idea that the glycine
zipper motif of Ab drives the formation of membrane
pores, Kim et al demonstrated that Gly-to-Leu substitu-
tions in this motif (particularly the G37L substitution)
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and reduce Ab toxicity in cultured Neuro 2a neuroblas-
toma cells. However, these studies did not directly
demonstrate that the G37L substitution disrupted the
formation of Ab oligomers, or that oligomer disruption
was the basis for the reduced toxicity in cell culture.
Hung et al [14] compared the toxicity of synthetic Ab
1-42 containing G25L, G29L, G33L or G37L substitu-
tions (generally termed GSL peptides) to wild type Ab
in primary mouse cortical neurons. These substitutions
were all found to be less toxic than wild type Ab,w i t h
the G33L and G37L substitutions having the greatest
reduction in toxicity. The reduced toxicity of these GSL
peptides was correlated with reduced formation of smal-
ler Ab oligomers (dimers, trimers, tetramers, and penta-
mers) in vitro. These researchers also found that the
GSL peptides had increased rates of fibril formation
using an in vitro Thioflavin T assay. Harmeier et al [15]
examined the role of G29 and G33 in Ab 1-42 toxicity
and oligomerization, and found that substitutions at
G33 (G33A or G33I) dramatically reduced Ab toxicity
in neuroblastoma cells and biased in vitro oligomeriza-
tion towards higher molecular weight forms. These
researchers also demonstrated that unlike wild type Ab,
G33-substituted Ab did not inhibit hippocampal LTP or
disrupt eye formation in a Drosophila transgenic Ab
expression model.
In theory, the relevance of the glycine zipper to Ab
toxicity could be explored in transgenic mouse models
expressing Amyloid Precursor Protein (APP) that con-
tains substitutions in the glycine zipper motif. However,
this motif has been demonstrated to play a role in the
dimerization of APP, and substitutions in the motif alter
APP proteolytic processing and Ab production [16,17],
thus confounding any interpretations of this hypotheti-
cal model. We have therefore employed a transgenic C.
elegans model [18] that directly expresses Ab42 to assay
effects of glycine zipper substitutions, particularly G37L,
on toxicity and amyloid formation, neither of which has
been previously tested in vivo. To address the important
issue of whether the correlations between the effects of
glycine zipper substitutions on oligomerization and toxi-
city are causally linked, we used multiple cell models to
ask whether G37L substitutions are actually anti-toxic, a
prediction of the toxic oligomer model. Finally, we used
second site substitutions in Ab G37L to test rigorously
structural predictions of the glycine zipper model in
vivo.
Results
Ab42 G37L is less toxic than wild type Ab in vivo
We have previously described and characterized a trans-
genic C. elegans model in which induction of human
Ab42 expression leads to intracellular accumulation of
Ab in body wall muscle cells, resulting in a highly repro-
ducible paralysis phenotype [5,18]. To determine if a
G37L substitution in Ab would alter toxicity in this
model, we generated transgenic strains (chromosomally-
integrated transgenic arrays) with inducible muscle-spe-
cific expression of Ab G37L, using either a dominant
morphological marker [pRF4, rol-6(su1006), dominant
Roller phenotype] or GFP expression [pCL26, Pmtl-2::
GFP, constitutive intestinal GFP] as co-transformation
markers. We compared the paralysis kinetics of two
independent strains [CL3523 (Pmyo-3::Ab G37L mini-
gene + pRF4) and CL2621 (Pmyo-3::Ab G37L minigene
+ pCL26)] to paired control transgenic strains expres-
sing equivalent levels of wild type Ab (CL4176 and
CL2659, respectively). (See Additional file 1 Table S1 for
all transgenic C. elegans s t r a i n su s e di nt h i ss t u d y . )A s
shown in Figure 2 (panels A and B), both Ab G37L
strains had dramatically reduced rates of paralysis in
comparison to the control strains. Despite the reduced
paralysis rates, these strains had similar levels of Ab
expression (Figure 2C), and the distribution of immu-
noreactive intracellular Ab deposits was not changed in
the Ab G37L strains (Figure 2D). We did note a variable
pattern of immunoreactive bands between strains
Figure 1 Schematic model of hypothetical glycine zipper-
mediated interaction between Aba-helical regions. Model of
possible packing arrangement between C-terminal regions (residues
24-39) of neighboring Ab molecules. The glycine zipper interface is
represented by the jagged line; residue G37 is highlighted in red.
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Page 2 of 17(arrow, Figure 2C), but this did not consistently corre-
late with genotypes or phenotypes. In addition, a signifi-
cant ultrastructural difference was observed between
muscle cells expressing wild type and G37L variant Ab:
abnormal mitochondria with reduced electron density
("light” mitochondria) were observed in the large
majority (> 85%) of body wall muscle cells expressing
wild type Ab while these were exceedingly rare in
worms expressing Ab G37L (Figure 2E, 1/71 muscles
scored, 9 worms sectioned).
The reduced toxicity of Ab G37L in the transgenic C.
elegans model could theoretically be due to the
Figure 2 Reduced toxicity of Ab G37L expressed in C. elegans. A. Representative plot of paralysis onset in transgenic worms induced to
express Ab wild type (strain CL4176) or Ab G37L (strain CL3523). In both of these strains the transgenes are marked with the dominant Roller
mutation rol-6(su1006). B. Paralysis plot for an independent pair of transgenic strains induced to express Ab wild type (CL2659) or Ab G37L
(CL2621). In both of these strains the transgenes are marked with the intestinal GFP marker Pmtl-2::GFP. C. Representative immunoblot of worm
protein extracts (20 μg/lane) probed with anti-Ab monoclonal antibody 6E10. Lane 1, 25 ng synthetic Ab1-42; lane 2, CL4176 (Ab wild type);
lane 3, CL2659 (Ab wild type); lane 4, CL3523 (Ab G37L); lane 5, CL2621 (Ab G37L). Note that although the overall patterns of oligomeric Ab
bands were similar in strains expressing Ab wild type or Ab G37L, differences did appear in the region of dimeric Ab (arrow). D. Immunostaining
with mAb 6E10 of transgenic worms expressing Ab wild type (upper panel) or Ab G37L (lower panel). Nuclei stained with DAPI (blue), 6E10
immunoreactivity in red. Size bar = 10 μm. E. Electron micrographs of sections of transgenic worms fixed by high pressure freezing. Left panel,
section through body wall muscle of worm expressing Ab wild type (CL4176). Note abnormal “light” mitochondria (arrows). Right panel,
equivalent section through body wall of transgenic worm expressing Ab G37L (CL3523). Note normal dark mitochondria (arrows). S =
sarcomeres, N = nucleus, M = mitochondria. Size bar = 1 μm.
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G37. We therefore constructed a transgenic line expres-
sing Ab G37F, and found that this substitution also dra-
matically reduced Ab toxicity in the C. elegans model
(Figure 3). An alternative interpretation for the reduced
toxicity of the G37L substitution is that the glycine-to-
leucine substitution simply increases the hydrophobicity
of Ab. However, we observed that a transgenic strain
expressing the Ab triple glycine zipper substitution
(G29L G33L G37L) was actually slightly more toxic
than Ab G37L. While the model of Kim et al [13] pre-
dicts that the reduced toxicity of glycine zipper substitu-
tions results from an interruption of a-helix packing,
these substitutions could also conceivably interfere with
b-sheet formation. We have previously demonstrated
that a leucine-to-proline substitution at Ab position 17
(L17P), which is strongly predicted to interfere with b-
sheet formation by the central hydrophobic core of Ab,
blocks in vivo amyloid formation [19]. We therefore
compared the toxicity of induced Ab L17P to Ab wild
type and Ab G37L, and observed that the toxicity of the
L17P variant was comparable to that of wild type Ab
Figure 3. While this result does not rule out the possibi-
lity that the G37L substitution disrupts b-sheet forma-
tion, it does show that interfering with the ability of Ab
to form b-sheet structure does not by itself reduce Ab
toxicity in this model.
We have previously shown that the Ab sequence can
act as a modular aggregation domain, such that the C-
terminal addition of Ab 3-42 to GFP converts this nor-
mally soluble protein to a strongly aggregating one [20].
Introduction of an L17P substitution into the Ab
sequence reverses this aggregation capacity, thus GFP::
Ab L17P is soluble when expressed in C. elegans or hip-
pocampal neurons. To test if the G37L substitution
reduced Ab toxicity by similarly blocking Ab aggrega-
tion, we examined the distribution of GFP::Ab G37L
expressed in C. elegans muscle. As shown in Figure 4A,
GFP::Ab G37L readily formed inclusions in C. elegans,
demonstrating that the G37L substitution does not
interfere with Ab-driven aggregation in vivo.
Constitutive expression of wild type Ab in C. elegans
body wall muscle leads to the formation of intracellular
amyloid deposits detectable with amyloid dyes Thiofla-
vin S [5,19] or X-34 [21]. We generated worms with
constitutive Ab G37L expression in muscle (Punc-54::Ab
G37L minigene) and found that this Ab variant did not
make detectable amyloid (Figure 4B, C). Thus, while the
G37L substitution did not block general Ab aggregation,
it did prevent amyloid formation in this in vivo model.
Synthetic Ab G37L is anti-toxic in Neuro 2a cells
To investigate whether Ab G37L is anti-toxic, we first
turned to a transformed cell culture model where Ab
exposure could be carefully controlled. Kim et al (13)
reported that synthetic Ab G37L was significantly less
toxic to Neuro 2a cells than synthetic wild type Ab.T o
determine if the presence of Ab G37L could inhibit the
toxicity of wild type Ab to Neuro 2a cells, increasing
amounts of Ab 1-42 G37L were added to wild type Ab
1-42 immediately after solubilization of these peptides.
(Before solubilization, the peptides were rendered mono-
meric by pre-treatment with HFIP and subsequent
desiccation.) As shown in Figure 5A, progressive addi-
tion of Ab G37L led to a progressive reduction of wild
type Ab toxicity, such that at equal concentrations of
wild type and G37L Ab, loss of cell viability was equiva-
lent to that of the vehicle control. These results could
be due to a direct interaction between the wild type and
variant peptide (e.g., Ab G37L inhibiting the formation
of a toxic oligomer by wild type Ab), or an indirect
effect (e.g., competition between the peptides for some
toxic target). To distinguish between these possibilities,
we compared the toxicity of equimolar mixtures
Figure 3 Relative paralysis rates of worms expressing wild type or variant Ab. Representative plot of transgenic worms induced to express
Ab. Strains used were: CL2654 (Ab L17P), CL2659 (Ab wild type), CL2666 (Ab G29L G33L G37L), CL2621 (Ab G37L) and CL2716 (Ab G37F).
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individual peptides were solubilized and allowed to oli-
gomerize separately for 20 min before addition to the
Neuro 2a cells. As shown in Figure 5B, individual incu-
bation of the peptides prevented Ab G37L from interfer-
ing with wild type Ab toxicity (P < 0.05, Student’sT -
test), consistent with the model that the Ab G37L var-
iant can directly interfere with the formation of toxic
oligomers by wild type Ab.
Synthetic Ab G37L is anti-toxic in mammalian
hippocampal neurons
In the experiment described above, we did not bio-
chemically characterize the oligomerization of the Ab
peptides, and interpretation of the toxicity assay was
limited by the use of immortal cultured cells. Ab oligo-
mers have been shown to be highly toxic when added to
primary hippocampal neurons [22], so we attempted to
replicate the Neuro 2a findings in a more disease-rele-
vant primary neuronal culture system. We first exam-
ined the ability of synthetic Ab 1-42 G37L to form
oligomers in vitro, using two oligomerization protocols:
the globulomer protocol of Barghorn et al [23] and the
ADDL (Ab Derived Diffusible Ligand) protocol of Lam-
bert et al [24]. As shown in Figure 6A, synthetic Ab
G37L readily formed oligomers in vitro,a n df o r m e d
higher molecular weight species than wild type Ab 1-42,
as has been previously reported for glycine-substituted
Ab peptides (14,15). The toxicity of G37L ADDLs was
assayed using primary hippocampal neurons as pre-
viously described [25,26]. Drebrin expression was used
as a specific read-out of Ab toxicity, as this is a critical
dendritic spine protein, and synapses are key targets
of ADDL toxicity [25]. Exposure of hippocampal neu-
rons to ADDLs (500 nM) formed from wild type Ab
caused a significant reduction in drebrin detected by
Figure 4 Effect of G37L substitution on Ab mediated aggregation and b-amyloid formation. A. Digital overlay of differential interference
contrast (DIC) and epifluorescence images of live transgenic worms expressing GFP::Ab fusion proteins. Top panel, third larval stage worm
expressing GFP::Abwild type fusion protein (strain CL1332). Note GFP inclusions in body wall muscle. Middle panel, third larval stage worm
expressing GFP::Ab L17P fusion protein (strain CL1364). Note diffuse GFP in body wall muscle. Lower panel, third larval stage worm expressing
GFP::AbG37L fusion protein. Note similar GFP inclusions as observed in worms expressing GFP::Ab wild type (top panel). Size bar = 100 μm. B.
Amyloid formation in transgenic worms with constitutive muscle expression of Abwild type or G37L. DIC/epifluorescence images of live adult
transgenic worms stained with amyloid-specific dye X-34 (33). Top panel, CL2006 (wild type Abexpression). Note lateral amyloid deposits (small
arrows) in body wall muscle and non-specific staining of the buccal cavity (large arrow). Lower panel, CL2564 (AbG37L). Muscle X-34 deposits are
undetectable, although staining is still seen in the buccal cavity (large arrow). Size bar = 100 μm. C. Quantification of X-34 deposits in CL2006
(Abwild type), CL2564 (AbG37L), and CL802 (control non-transgenic) worms. Error bars = S.E.M.
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A comparable reduction was not observed when neu-
rons were exposed to ADDLs derived from Ab G37L
(Figure 6 B, C, D). The reduced toxicity of G37L
ADDLs did not result from the inability of these oligo-
mers to bind to hippocampal neurons, as immunostain-
ing with an oligomer-specific antibody (NU1) revealed a
robust association of these ADDLs with neurons (Figure
6E). The Ab G37L peptide was also anti-toxic in this
model, as mixing together wild type and G37L peptides
resulted in non-toxic ADDLs (Figure 6F). However,
unlike the situation in Neuro 2a cells, the Ab G37L was
anti-toxic even when pre-incubated with primary neu-
rons before addition of wild type Ab ADDLs (Additional
File 1 Figure S1).
Deposition of hyper-phosphorylated tau is an impor-
tant component of Alzheimer’sp a t h o l o g y ,a n dA b
ADDL oligomers have been shown to induce tau hyper-
phosphorylation in hippocampal neurons in culture [27].
We therefore also compared the abilities of wild type
and G37L ADDLs to induce tau phosphorylation. We
treated primary hippocampal neuronal cultures with
ADDLs composed of wild type, G37L, or sequence-
scrambled Ab 1-42, and phospho-tau levels were quanti-
fied by immunofluorescence imaging after staining with
PHF-1, an antibody that recognizes AD-related tau
phosphorylation at residues Ser396 and Ser404. Vehicle-
treated controls demonstrated low levels of phospho-tau
(Figure 7A), similar to those observed in untreated neu-
rons, whereas neurons treated with 0.5 mM wild type
ADDLs had higher phospho-tau levels after 18 hours
( F i g u r e7 D ) .N od i f f e r e n c ew a so b s e r v e di nn e u r o n s
treated with either 0.5 mM scrambled ADDLs or G37L
ADDLs (Figures 7B and 7C) at 18 hours compared to
vehicle. Statistical analysis of quantitative immunofluor-
escence data revealed a twofold (P < 0.01) increase in
tau phosphorylation in neurons treated with the wild
type at 4 hours compared to vehicle, and a fourfold (P <
0.01) increase in tau phosphorylation at 18 hr (Figure
7E). Neither G37L nor scrambled ADDLs showed phos-
pho-tau levels significantly different from vehicle-only
treated neurons at either time (Figure 7E).
Adenovirus-transfected Ab G37L is anti-toxic in primary
cortical neurons
In the C. elegans model, cells were exposed to Ab pro-
duced endogenously from an inducible transgene, rather
than added exogenously as in the experiments described
above. To replicate this pattern of Ab expression in
mammalian neurons, we turned to an inducible adeno-
virus transfection system [28,29]. This system employs
engineered adenovirus that contain a signal peptide::Ab
1-42 minigene (directly analogous to the Ab minigene
used in the worm model) under control of a doxycy-
cline-inducible promoter. In this model, doxycycline
induction after transfection of rat primary cortical neu-
rons with a viral vector expressing wild type Ab 1-42
leads to a significant increase in toxicity (measured by
appearance of apoptotic neurons or reduced synapto-
physin staining) compared to uninduced transfected
neurons. As shown in Figure 8A, we found that neurons
Figure 5 Toxicity of Ab wild type and Ab G37L peptides on
Neuro 2a cells. Relative viability of Neuro 2a cells after treatment
with Ab wild type and Ab G37L peptides for 24 hours, either singly
or in various combinations. Viability was measured by the MTT assay
and normalized to the vehicle-treated control cells. A. Neuro 2a
cells were treated with 4 μMA b wild type that had been mixed
with from 0-4 μMA b G37L for 20 min at RT before addition to the
cells. The viability of each mixture was significantly different from
that of Ab wild type alone, and there was no significant difference
in the viability of the vehicle control and an equimolar mixture of
Ab wild type and Ab G37L (Student’s t-test). Overall, Ab G37L
mitigated the toxicity of Ab wild type in a linear dose dependent
manner (R
2 = 0.98). B. Neuro 2a cells were treated as described
above with 4 μMA b wild type and/or 4 μMA b G37L. Note that the
ability of Ab G37L to inhibit Ab wild type toxicity is lost when these
peptides are oligomerized separately before addition to the Neuro
2a cell culture. (* P < 0.05, NS = not significant).
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Page 6 of 17Figure 6 Toxicity of Ab wild type and Ab G37L oligomers (ADDLs) in primary hippocampal cultures. A. SDS-PAGE fractionation of
oligomers formed from synthetic Ab1-42 wild type or G37L. The left panel displays oligomers formed using the “globulomer” preparation of
Barghorn et al [21]. The right panel displays oligomers formed using the “ADDL” preparation originally described by Lambert et al [24].
Monoclonal antibody 6E10 recognizes an epitope included in Abresidues 16-24; mAb NU1 preferentially binds oligomeric Ab. Note that for both
oligomer preparations Ab G37L tends to form higher molecular weight species. B-D . Representative epifluorescence images of anti-drebrin
staining of embryonic rat hippocampal neurons treated after 21 days in culture for 24 hr with vehicle (B), 500 nM Ab wild type ADDLs (C), or
500 nM Ab G37L ADDLs (D). Note the strong reduction of drebrin staining is induced by exposure to wild type, but not G37L, ADDLs. E.
Hippocampal neurons treated with Ab G37 ADDLs, washed, fixed, and probed with anti-Ab oligomer antibody NU1. Note robust binding of the
Ab G37L ADDLs to neurons. F. Quantification of drebrin immunoreactivity in hippocampal neurons exposed to Ab wild type or G37L ADDLs.
Exposure to Ab wild type ADDLs significantly reduced drebrin immunoreactivity relative to vehicle-treated neurons (*P < 0.01), but no significant
reduction was found for Ab G37L ADDLs or ADDLs formed from a 1:1 mixture of Ab wild type and G37L (Tukey Multiple Comparisons test).
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Page 7 of 17Figure 7 Effect of Ab wild type and G37L ADDL exposure on tau hyperphosphorylation. A. - D. Representative epifluorescence images of
cultured embryonic hippocampal neurons that were exposed for 18 hr to vehicle (A), 500 nM Ab G37L ADDLs (B), 500 nM Ab scrambled ADDLs
(C), or 500 nM Ab wild type ADDLs (D), then fixed and probed with anti-phospho tau monoclonal antibody PHF-1. Note strong increase in PHF-
1 staining only in neurons treated with Ab wild type ADDLs. E. Quantification of PHF-1 staining. Exposure to Ab wild type produced significant
increases in PHF-1 staining relative to control at 4 hr (204% ± 13; p = 0.0023; n = 5) and 18 hr (416% ± 48; p = 0.0041; n = 5); none of the other
treatments significantly increased PHF-1 staining (Student’s T-test, * P < 0.005).
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G37L did not show a significant increase in apoptotic
nuclei after doxycycline induction, consistent with the
reduced toxicity of this Ab variant. Co-transfection with
both Ab wild type and G37L-expressing adenovirus also
failed to significantly increase the appearance of apopto-
tic nuclei relative to uninduced controls, again demon-
strating the anti-toxic effects of Ab G37L expression.
Interestingly, Ab L17P is as toxic as Ab wild type in this
model, consistent with the Ab L17P toxicity observed in
the transgenic C. elegans model.
As an alternative measure of Ab toxicity, we also
assayed the effect of transfected Ab on synaptophysin, a
well-studied presynaptic marker. As shown in Figure 8B,
doxycycline induction of Ab wild type significantly
reduces immuno-detectable synaptophysin. However,
induction of transfected Ab G37L by itself or Ab G37L
+A b wild type does not result in statistically significant
decreases in synaptophysin compared to uninduced con-
trols (Figure 8C), consistent with the anti-toxic effects
of Ab G37L.
Second site substitutions restore toxicity to Ab G37L
A rigorous test of the glycine zipper model would be to
determine if compensatory second site substitutions
based on this model can restore toxicity to Ab G37L. In
models of glycine zipper interactions in bacterial chan-
nel proteins, the glycine-containing face of a membrane
a-helix is opposed by the “backside” (i.e. opposite the
glycine-containing face) of a neighboring a-helix [13]. If
this model were applied to the formation of membrane-
associated Ab oligomers, Ab G37 would be predicted to
interact with the non-glycine face of an a-helix formed
by a neighboring Ab molecule. The specific residues
interacting with Ab G37 would therefore be those resid-
ing on the other side of the predicted Aba -helix, which
are potentially N27, I31, or M35 (see Figure 1). If the
disruption of the glycine zipper by the G37L substitu-
tion is due to the larger leucine residue sterically hinder-
ing a-helix packing, substituting a smaller amino acid
opposite the leucine substitution could potentially com-
pensate for the leucine substitution and thereby restore
a-helix packing and Ab toxicity. We therefore generated
a set of transgenic worms expressing doubly-mutated
Ab: N27G G37L; I31G G37L; and M35G G37L. As
shown in Figure 9A, all these second site substitutions
increased the toxicity of Ab G37L. Ab with single
N27G, I31G, or M35G substitutions were not more
toxic than Ab wild type (Figure 9B).
Discussion
Although the b-amyloid peptide is toxic in a wide range
of model systems, the specific toxic form of Ab has not
been convincingly identified, nor is it clear if the same
Figure 8 Toxicity of wild type and variant Ab in adenovirus
transfection model. Cultured rat cortical neurons were transfected
with adenovirus engineered for doxycycline-inducible expression of
wild type or variant Ab, and toxicity was assayed by scoring of
apoptotic nuclei or synaptophysin expression. A. Relative toxicity
(pyknotic nuclei fraction) in neurons transfected with Ab-expressing
adenovirus with (+ Dox) and without induction. Transfection with
adenovirus expressing Ab wild type or Ab L17P leads to significant
toxicity after transgene induction (* P < 0.001), while transfection
with adenovirus expressing Ab G37L, or co-transfection with Ab
wild type and Ab G37L, does not lead to significant toxicity after
doxycycline induction. B. Representative processes containing
synapses labeled with synaptophysin in Ab wild type and Ab G37L
expressing neuronal cultures. Control panel refers to non-induced
cultures. Scale bar, 5 μm. C. Analysis of puncta density (number of
synapses per 25 μm of neurite) indicated fewer synapses in Ab wild
type expressing cells compared to non-induced controls.
Intraneuronal Ab G37L and co-expression of Ab wild type and Ab
G37L resulted in no significant synapse alterations. Data from 3-5
different cultures from 3 independent isolations. n (neurites) = 154
Ab wild type, 98 Ab G37L, 118 Ab wild type + G37L. (* = P < 0.001,
NS = not significant, P > 0.1). Error bars represent SEM.
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ous studies have pointed to soluble, oligomeric Ab as
being the key toxic species, but there is no general
agreement about the subunit composition or quaternary
structure of this toxic oligomer. Defining the toxic Ab
species is difficult because while the oligomeric nature
of Ab can be assayed before it is added to cells (e.g.,
size exclusion profiling of ADDLs prepared from syn-
thetic Ab) or after Ab is expressed (e.g., immunoblotting
protein preparations from transgenic Ab-expressing ani-
mals), capturing the toxic species “in action” has not
been feasible. Direct biochemical approaches may also
be problematic if the key Ab toxic species is unstable
and/or a minor component of total Ab.T oa v o i dt h e s e
problems we have assayed the toxicity, in vitro and in
vivo,o fas e to fA b variants designed to test a specific
model of the toxic Ab species. Our results demonstrate
a critical role for C-terminal glycine residues in the for-
mation of toxic Ab oligomers, and thereby serve to sig-
nificantly constrain structural models for these toxic
oligomers.
We find that Ab G37L is less toxic than Ab wild type
both in vivo and in primary neuronal culture. Our
results are complementary to those of Harmeier et al
[15], who showed that G33A or G33I substitutions also
reduce Ab toxicity in vitro and in vivo. (These authors
did not report testing G37 substitutions.) These com-
bined studies strongly argue that it is the disruption of
the glycine zipper itself, rather than the alteration of any
specific residue, that reduces Ab toxicity.
How does Ab assemble into the toxic oligomeric spe-
cies? A large fraction of Ab is membrane-associated
Figure 9 Second site mutations partially restore Ab G37L toxicity. A. Paralysis plots of transgenic C. elegans expressing wild type, G37L, or
double mutant Ab. Note that the transgenic worms expressing the candidate compensatory mutations all paralyze faster than worms expressing
Ab G37L. B. Paralysis plot of transgenic C. elegans expressing single compensatory mutations. None of these single site mutations confer obvious
hyper-toxicity.
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AD brain (G. McColl and A. Bush, personal communi-
cation). We speculate that like a number of vertebrate
antimicrobial peptides, Ab exists in a b-sheet or random
coil configuration when soluble extracellularly or in the
cytoplasm, but converts to an a-helical structure upon
membrane association. This conversion has been
demonstrated by biophysical methods for plasticins
[30,31] and bombinins [32], anti-microbial peptides that
contain Gly-XXX-Gly-XXX-Gly motifs. Interestingly, Ab
has also been shown to have anti-microbial activity [33].
While x-ray crystal structures have not been determined
for small anti-microbial peptides, the first atomic struc-
ture for an a-helical pore-forming toxin (ClyA) has
recently been described [34]. We note that this study
reveals a b-sheet “tongue” present in the soluble form of
ClyA that converts to a-helical structure upon mem-
brane insertion. This tongue region also contains a gly-
cine zipper motif (...G
180AAAGVVAG
188...), and a
glycine-to-valine substitution at position 180 has been
shown to compromise hemolytic activity of this toxin
[35]. Thus, although ClyA is significantly larger than
Ab, these structural data are consistent with our model
of a-helix formation by the glycine zipper region of Ab
occurring upon membrane association.
Our observation that AbG 3 7 Ld o e sn o tf o r md e t e c t -
able amyloid in vivo differs from the results of Hung et
al [14], who found that Ab G37L had enhanced fibriliza-
tion in vitro. These results can be reconciled if there are
significant differences in the amyloid seeding step [36]
under in vivo and in vitro conditions. It has been pro-
posed that the formation of a-helical structure by mem-
brane-associated Ab drives the formation of oligomers
and therefore a local increase in Ab concentration, and
this localized Ab concentration catalyzes b-sheet forma-
tion and amyloid formation [37]. a-helical intermediates
have been observed preceding amyloid formation by Ab
[38]. We suggest that in the C. elegans model, glycine
zipper-driven oligomerization at membranes is required
to reach the critical local Ab concentration to initiate
amyloid formation, and this oligomerization and subse-
quent amyloid formation is blocked by the G37L substi-
tution. However, other interactions (perhaps influenced
by overall peptide hydrophobicity) may drive the forma-
tion of initial amyloid seeds in vitro, and thus the gly-
cine-substituted Ab peptides have faster amyloid
formation rates under these conditions.
While Ab G37L appears anti-toxic in both Neuro-2a
cells and primary hippocampal neurons, we did observe
different co-incubation requirement for these two model
systems: inhibition of wild type Ab toxicity required
immediate co-oligomerization with Ab G37L in the
Neuro-2a model but not in the primary neuronal culture
model. One possible explanation for these differences is
that Ab oligomers show highly preferential binding to
synaptic sites in primary neurons [25], suggesting there
may be a limiting number of Ab binding sites in these
neurons. Consequently, unoligomerized Ab G37L may
not only counter the toxic oligomerization of wild type
Ab,b u to l i g o m e r i z e dA b G37L may also compete with
wild type oligomers for binding to relevant sites on the
neuronal plasma membrane. Competition for binding
sites may not be relevant to Ab toxicity in the undiffer-
entiated Neuro-2a cells used in our study.
Our demonstration of anti-toxic effects of Ab G37L in
cell culture and primary neurons clearly supports the
oligomer model for Ab toxicity, although we cannot
readily infer the subunit composition of these oligomers
from our experiments. We have observed variable pat-
terns of presumed Ab oligomeric bands in strains
expressing different Ab variants, but we have been
unable to associate a specific oligomeric band with toxi-
city. A caveat to this approach to interpreting immuno-
blots is that we do not know to what degree they
capture the true distribution of Ab oligomers in vivo.I t
has been reported that different biophysical forms of Ab
actually show similar oligomer banding patterns after
SDS-PAGE [39].
E v e nt h o u g hK i me ta lh a v ed e m o n s t r a t e dt h a tt h e
G37L substitution blocks Ab channel formation in syn-
thetic membranes, and we have rigorously demonstrated
that Ab G37L has reduced toxicity in multiple models,
at present we have no direct evidence that the reduced
toxicity of Ab G37L is due to effects on membrane con-
ductance per se.W ea l s on o t et h a tA b need not form
pores in order to disrupt membrane function; instead it
could result from Ab altering the local membrane envir-
onment such that the conductance of endogenous ion
channels (e.g., the NMDA receptor) is altered. An
appealing component of the membrane disruption
hypothesis is that it explains why Ab is toxic when both
outside cells (e.g., hippocampal neurons exposed to
ADDLs) and inside cells (e.g., intracellular accumulation
in C. elegans): in either case, Ab has access to the
plasma membrane. In theory, intracellular Ab could also
damage organelle membranes, such as the ER or mito-
chondrial membranes. Ab accumulation has often been
associated with mitochondrial dysfunction [40-42], and
we have observed mitochondria with abnormal ultra-
structure specifically in C. elegans muscles accumulating
Ab (Figure 2). Given that we did not observe abnormal
mitochondria in transgenic worms expressing Ab G37L,
we speculate that expression of wild type Ab in this
model may lead to disruption of mitochondrial mem-
brane function.
Introduction of second site mutations into Ab G37L
resulted in enhanced toxicity. This compensatory inter-
action is most striking in the N27G G37L variant, which
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Additional file 1 Figure S2). However, interpretation of
the enhanced toxicity in Ab I31G G37L and Ab M35G
G37L relative to Ab G37L is complicated by the obser-
vation that the single Ab I31G and Ab M35G strains
produce reduced levels of Ab relative to the control Ab
wild type strain but show comparable paralysis rates,
suggesting these single substitutions may be more toxic
than wild type Ab. If this is the case, we cannot exclude
the possibility that these second site mutations increase
the toxicity of Ab G37L by an additive rather than com-
pensatory mechanism. If the correct interpretation is
that these second site mutations all increase toxicity by
restoring helix packing in the glycine zipper region, our
results imply that there is no single packing arrange-
ment involved in the formation of toxic Ab oligomers,
as all three of the tested second site substitutions
enhanced the toxicity of Ab G37L. An alternative expla-
nation for the enhanced toxicity of the double mutant
Ab is that it is the total number of glycine residues in
the C-terminal region of Ab that is the key determinant
of toxicity. Although we cannot exclude this possibility,
it is difficult to develop a molecular model that would
account for this explanation.
We did undertake multiple attempts to generate trans-
genic worms with a leucine substitution at the single
glycine residue in Ab that lies outside the glycine zipper
region (G9), which we predicted would not reduce toxi-
city. Unfortunately, all of the chromosomally-integrated
transgenic lines recovered in this series of experiments
did not produce detectable Ab, an experimental failure
that did not occur for any of the other glycine substitu-
tions we attempted. It has also been more difficult to
recover transmitting lines expressing wild type Ab,p r e -
sumably due to selection against lines expressing this
toxic peptide (even under non-induced conditions).
Thus, while we do not have data for the G9L control,
we speculate that this variant may be at least as toxic as
wild type Ab.
Although Ab G37L appears to be significantly less
toxic than wild type Ab when expressed in C. elegans,i t
does not appear to be non-toxic, as transgenic worms
expressing Ab G37L still ultimately become paralyzed. A
possible explanation for this observation is that there
may be two components to Ab toxicity in this C. elegans
model: a specific toxicity due to activity of Ab oligo-
mers, and a more general toxicity due to accumulation
of misfolded protein. There is strong evidence that accu-
mulation of misfolded proteins in C. elegans muscle can
lead to a disruption of cellular protein handling (pro-
teostasis) [43,44], and expression of an aggregation-
prone polyglutamine::YFP fusion protein in C. elegans
muscle leads to reduced motility [45]. Ab G37L and the
o t h e rv a r i a n t se x a m i n e di nt h i ss t u d ya l lm a k e
immunoreactive cytoplasmic inclusions when expressed
in C. elegans muscle, consistent with our transgenic
inducible system generally producing Ab levels that
exceed cellular protein handling capacity.
Our studies predict that compounds that specifically
interfere with Ab glycine zipper formation will block Ab
toxicity, and therefore would be candidate therapeutics
for Alzheimer’s disease. Computational methods exist to
design peptides that specifically disrupt helix-helix inter-
actions in protein transmembrane regions [46,47]; in
theory this approach can be used to target the Ab gly-
cine zipper. Extending this approach to develop practical
therapeutic compounds for Alzheimer’s disease will
likely require identification of brain-accessible small
molecules that specifically inhibit Ab glycine zipper
interactions. Our studies also suggest the possibility that
there may exist in the human population alleles of APP
that encode substitutions in the glycine zipper regions
that protect against Alzheimer’s disease.
Methods
Construction and characterization of transgenic C.
elegans strains
Transgenic constructs designed to produce temperature-
inducible expression of substituted Ab in C. elegans
body wall muscle were generated from expression con-
struct pCL12 (Pmyo-3::signal peptide::Ab 1-42::long 3’
UTR) [18]. The inclusion of an abnormally long 3’
untranslated region in this construct leads to transgene
expression being regulated by the mRNA surveillance
system. Introduction of pCL12-derived transgenes into a
genetic background containing a temperature-sensitive
mutation in an essential RNA surveillance gene [smg-1
(cc546)] results in increased transgene expression at
non-permissive temperatures. Transgenes expressing
variant Ab were typically generated by in vitro mutagen-
esis [Gene Tailor kit (Invitrogen) or Site Directed Muta-
genesis Kit (Stratagene)] of the signal peptide::Ab 1-42
minigene cassette in a donor plasmid. The mutated Ab
minigene was then used to replace the wild type Ab
minigene sequence in pCL12 by restriction enzyme clea-
vage (Nhe I/Sac I) and religation. A transgene with mus-
cle expression of GFP::Ab G37L was similarly
constructed by in vitro mutagenesis of pCL111 (Pmyo-
3::GFP::Ab 3-42). All plasmid constructs were confirmed
by DNA sequencing.
C. elegans strains containing multicopy, chromoso-
mally-integrated transgenes were constructed as pre-
viously described [18]. Briefly, Ab expression plasmids
(100 ng/μl final concentration) were co-microinjected
with marker plasmids [100 ng/μl final concentration of
either pRF4 expressing dominant Roller morphological
marker rol-6 (su1006) or pCL26 expressing constitutive
intestinal GFP (Pmtl-2::GFP)] into smg-1(cc546)w o r m s .
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unstable extrachromosomal transgenes, and then strains
were derived containing fully stable chromosomally-inte-
grated transgenes by irradiation and subsequent selec-
tion (5). PCR and subsequent DNA sequencing was
performed to check the Ab genotype of transgenic
strains.
Paralysis assays
Quantification of paralysis rates for transgenic C. elegans
strains was done as previously described [48,49]. Briefly,
populations of third larval stage transgenic worms were
upshifted from 16°C to 25°C and the fraction of paral-
yzed fourth larval stage worms was scored every 2 hr
starting 12-18 hr after upshift (depending on transgenic
strains assayed). Triplicate populations (total n > 100)
were scored for each genotype in a paralysis assay, and
each paralysis assay was repeated at least three times.
Transgenic strains containing the rol-6 morphological
marker (which affects overall worm movement) repro-
ducibly showed slower absolute paralysis rates compared
to transgenic strains expressing the same Ab construct
but a GFP transgenic marker. All strain paralysis com-
parisons were therefore made between transgenic strains
using the same marker transgene.
Quantification of Ab expression in transgenic C. elegans
To quantify Ab accumulation in C. elegans (Supplemen-
tal Table 1), transgenic populations were harvested 24
hr after temperature upshift, and whole worm extracts
were fractionated by SDS-PAGE as previously described
[50]. After blotting, the fractionated proteins were
probed with anti-Abmonoclonal antibody 6E10 (Abcam,
#Ab10146) at 0.7 μg/ml, and Ab immunoreactivity was
visualized using HRP-conjugated secondary antibodies
(1:1000 dilution), ECL development (GE Osmonics), and
digital image acquisition (Image Station 2000R, Kodak).
Total Ab immunoreactivity was quantified using Image J
software to sum whole-lane immunoreactivity (i.e., all
oligomeric and monomeric bands as illustrated in Figure
2C). Ab immunoblot expression was normalized to
either CSTF64 (a ubiquitous, highly-expressed splicing
factor) immunoreactivity or total blotted proteins
assayed by Ponceau S staining.
C. elegans electron microscopy
Staged populations of transgenic C. elegans were shifted
as third larval stage worms from 16°C to 25°C for 24 hr,
then immediately harvested and subjected to high pres-
sure freeze fixation as previously described [51].
Culture and treatment of N2a cells
Neuro2a mouse neuroblastoma cells (N2a) were grown
in a 1:1 mixture of OptiMEM-I and DMEM (containing
GlutaMax and nonessential amino acids), supplemented
with 10% FBS. The cells were plated in poly-L-lysine-
coated 96 well plates at 10,000 cells/well in 100 μL med-
ium. Two days later, the cells were treated with wild
type (wt) and/or mutant (G37L) Ab42 peptides for 24
hours, whereupon their toxicity was assessed as a
decrease in the metabolic reduction of MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
to formazan. Briefly, 10 μl aliquots of MTT (5 mg/ml in
sterile PBS) were added to each well of cells for 2-4 hr
at 37°C, the reaction was stopped by adding 100 μl2 0 %
SDS in 50% N,N-dimethylformamide to each well, the
plates were incubated at 37°C overnight to dissolve the
purple formazan, and the absorbance was read at 560
nm. Frozen, dried preparations of monomerized Ab-wt
and Ab-G37L peptides were dissolved in DMSO at 1
mM, diluted to 100 μM with OptiMEM-I, and immedi-
ately combined with additional vehicle, and/or with each
other, to form mixtures that contained one or both pep-
tides at a concentration of 25 μM each. These were
allowed to sit at room temperature for 20 min, before
being added to the cells at a final concentration of 4
μM for each peptide. In this way, N2a cells were
exposed to either 4 μMA b-wt, 4 μMA b-G37L, a com-
bination of 4 μMA b-wt plus 4 μMA b-G37L that had
been incubated together for 20 min, or a combination of
4 μMA b-wt plus 4 μMA b-G37L that had been incu-
bated separately for 20 min before being added to the
cells together. In a variation of this protocol, the amount
of Ab-G37L peptide that was pre-incubated with 25 μM
Ab-wt was varied from 0-25 μM to determine how
much Ab-G37L was needed to counteract the toxicity of
Ab-wt peptide (applied to N2a at 4 μM). The amount of
DMSO in the medium was the same (0.4%) for all sam-
ples and controls. In each experiment 4-6 wells were
analyzed per treatment, and each experiment was
repeated at least 3 times.
Exposure of hippocampal neurons to ADDLs
Preparation of oligomeric Ab.A b oligomers (ADDLs)
were generated from synthetic Ab essentially as pre-
viously described [24,25]. Synthetic Ab peptide was
obtained from the following sources: Ab1-42 and Ab 1-
42 G37L from American Peptide Company Inc., Sunny-
vale, CA; scrambled Ab 1-42 and fluorescein amidite-
tagged Ab1-42 from AnaSpec, San Jose, CA; and addi-
tional Ab 1-42 G37L from Biosynthesis, Lewisville, TX.
Peptides were prepared as dried HFIP films, then dis-
solved in fresh, anhydrous DMSO (Sigma Hybri-Max D-
2650) to make a ~5 mM solution then diluted to ~100
μM with cold F12 media without phenol red (Biosource)
and aged 24 hr at 4°C. The samples were centrifuged at
14,000 g for 10 min at 4°C and the supernatants stored
at 4°C. Protein concentration was determined by Coo-
massie Plus protein assay (Pierce) with a BSA standard.
Gel electrophoresis of oligomerized Ab Samples were
diluted in F12 and mixed 1:1 with Laemmli sample buf-
fer (Bio-Rad) and electrophoresed at 125 V on a 4-20%
Tris-glycine gel (Novex, Invitrogen) with Tris-glycine-
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min. The gel (45 pmoles/lane) was silver stained with
SilverXpress (Invitrogen). Alternatively, the gel (15
pmoles/lane) was electroblotted onto Hybond ECL
nitrocellulose using 25 mM Tris, 192 mM glycine, 20%
methanol, 0.02% SDS, pH 8.3 at 100 V for 1 hr at 4°C.
The blot was blocked with 5% non-fat dry milk in TBS-
T (0.1% Tween-20 in 20 mM Tris-HCl pH 7.5, 0.8%
NaCl) for 45 min at RT, incubated with NU1 (1 mg/ml
in milk/TBS-T) for 2 hr at RT and washed 3 times with
TBS-T. The blot was incubated with HRP-linked anti-
mouse IgG (1:40,000 in milk/TBS-T; Amersham) for 60
min at RT, washed 3 times with TBS-T, rinsed 3 times
with dH20, developed with SuperSignal West Femto
Maximum Sensitivity substrate (Pierce) for 1 min and
read on a Kodak Image Station.
Preparation of primary hippocampal cultures Hippo-
campi from embryonic day 18 Sprague-Dawley rats were
used for the preparation of primary hippocampal cul-
tures. For the drebrin expression experiments, cultures
were prepared as previously described by Gong et al
[22], and cultured neurons were exposed to ADDLs at
21 D.I.V. For the tau phosphorylation experiments, the
primary cultures were prepared as described by Decker
et al [52], and the cultures were exposed to ADDLs at 9
D.I.V.
Detection of Ab binding to hippocampal neurons
ADDLs bound to mature hippocampal neurons were
detected using monoclonal antibody NU1 [53] or by
preparing fluorescent ADDLs (FADDLs) using biotiny-
lated Ab and streptavidin-conjugated quantum dots [54].
Immunocytochemistry, image acquisition, and analysis for
drebrin expression
The drebrin expression assay was performed as pre-
viously described [26]. Briefly, mature hippocampal cells
at 21 DIV are treated with the fluorescently tagged
ADDLs (FADDLs) for 24 hr. Treated cells were rinsed
to remove unbound Ab-assemblies and then fixed with
3.7% formaldehyde or 4% paraformaldehyde in Neuroba-
sal media (1:1 volume) for 20 min followed by an addi-
tional 20 min undiluted fixative. Cells were rinsed
extensively in PBS. Cover slips were incubated in block-
ing solution (10% normal goat serum in PBS without
0.1% Triton X-100) for 45 min at room temperature
(RT). Antibody against drebrin (Stressgen, Victoria, Brit-
ish Columbia, Canada) was used to identify dendritic
spines. It was diluted in blocking solution and incubated
on the cells overnight at 4°C. After rinses with PBS with
1% NGS, cover slips were incubated with appropriate
Alexa-Fluor-conjugated secondary antibodies (Invitro-
gen, Carlsbad, CA) diluted in PBS plus 1% NGS for 90
min at RT, rinsed extensively in PBS, and mounted with
ProLong Anti-fade media (Invitrogen).
Ab oligomer-bound neurons and dendritic branches
were imaged using a Leica (Exton, PA) TCS SP2 laser
confocal microscope with laser intensity and signal
detection settings held constant to allow for quantitative
comparison between experimental groups. Optical serial
sections of 0.5 μm intervals were taken through the cells
and reconstructed to generate a maximum intensity pro-
jection of z-stack images from individual cells and den-
dritic branches. After setting the intensity threshold,
dendritic segments of determined length were used to
determine drebrin integrated fluorescence intensity.
Spine Quantification was done using MetaMorph soft-
ware version 6.3 (Universal Imaging Corporation, Down-
ingtown, PA). All data are depicted as mean+/-SEM and
were analyzed by GraphPad Prism4 software (San Diego,
CA) for statistical significance using one-way ANOVA
and, if overall p <0 . 0 5 ,f o l l o w e db yam u l t i p l eg r o u p
comparison post hoc test (Tukey’s).
Immunocytochemistry, image acquisition, and analysis for
tau phosphorylation
Neurons were fixed with a solution of 4% paraformalde-
hyde/4% sucrose in PBS for 15 minutes, rinsed two times
in PBS and permeabilized for 7 minutes with Triton X-
100 (0.25%) in PBS. The permeabilization solution was
removed by rinsing three times in PBS. To prevent non-
specific binding of antibodies cells were incubated with a
Fish Skin Gelatin blocking buffer (FSGB) containing Fish
Skin Gelatin (0.5%) (Sigma-Aldrich) and Triton X-100
(0.1%) in PBS. Neurons were double immunolabeled by
overnight incubation at 4°C with mouse anti-PHF-1
(Ser396/404) (1:300) (provided by D. Volcado, Simon
Fraser University, Burnaby, Canada) and rabbit anti-
MAP2 (1:500) (Millipore, Temecula, CA) primary antibo-
dies, diluted in FSGB. The cells were rinsed 3 times in
PBS and incubated for 2 hours at 37°C with Cy-3 conju-
g a t e dd o n k e ya n t i - m o u s eI g G( 1 : 5 0 0 )( J a c k s o nI m m u -
noResearch Laboratories Inc., West Grove, PA) and
Alexa Fluor 488 goat anti-rabbit IgG (1:500) (Invitrogen)
secondary antibodies, diluted in FSGB. Cells were rinsed
3 times with PBS and twice with Milli-Q water to remove
buffer salts. Cover slips were mounted with Hoechst
33258 (10 μg/ml) (Sigma-Aldrich) in Elvanol.
Fluorescence imaging was carried out using a Leica
DMI 6000B microscope (Leica Microsystems Inc., Rich-
mond Hill, Canada) with a 63 × 1.4 plan apochromat
objective (Leica Microsystems Inc.). Images were
obtained with a cooled Orca-ER CCD camera (Hama-
matsu Photonics, Bridgewater, NJ) controlled by Meta-
Morph (Molecular Devices, Sunnyvale, CA). Due to
limitations in the digitizing range of the camera, pictures
of treated specimens and controls sometimes had to be
taken with different exposure times to avoid saturation
of the maximum pixel value. The results were
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analysis. Quantification of differences in tau phosphory-
lation was performed using Image J (NIH; Windows
Version) essentially as described [27]. In brief, an appro-
priate threshold was applied to eliminate background
signal before image analysis. Eighteen images per experi-
mental condition were analyzed and at least two experi-
ments using independent cultures were performed.
Changes in tau phosphorylation were estimated by com-
parison of total fluorescent pixel counts and the results
were combined for each condition. The total fluorescent
pixel counts were normalized by the number of cell
bodies in each image and by any difference in exposure
times. Statistical testing was carried out using Microsoft
Excel. Where applicable a student’su n p a i r e dt - t e s tw a s
performed. The mean value of 18 images from one
experiment constituted one sample (n). An a level of
0.01 was used. Values for changes in tau phosphoryla-
tion are presented as mean ± standard error of the
mean (SEM). Data for Ab 1-42 oligomers (0.5 μM) at 4
and 18 hours were provided by H. Decker, Simon Fraser
University, Burnaby, Canada.
Adenovirus transfections and experimental analysis -
Antibodies
Anti-synaptophysin (Chemicon International, Temecula,
CA) was used at a 1:250 dilution.
Adenoviral vector construction
The AdTet-On, AdTRE-LacZ, and AdTRE-Ab42 viruses
were previously described [28], G37L Ab42 mutation
was introduced by site-directed mutagenesis into the
original pTRE-Ab42 vector; the TRE cassette was sub-
cloned into pShuttle vector, and recombination with
pAdEasy-1 vector was achieved following manufacturer’s
instructions (Quantum Biotechnologies, Montreal, Que-
bec, Canada). Recombinant, E1-deleted replication-
defective adenoviral constructs were produced [30].
Viral titer was determined by cell death assay.
Neuronal cultures
For rat primary cultures, cortices were dissected from
embryonic day 18 Sprague Dawley rat brains (Charles
River Laboratories, Wilmington, MA), and neurons were
prepared as described previously [28]. Primary cortical
cultures were infected 11-13 days after plating at final
multiplicities of infection (m.o.i.) of 500. Equal amounts
of Ab42-WT and Ab42-G37L viruses were used when
added simultaneously. AdTet-On and AdTRE adenoviral
vectors were added into culture for 18 h at a 1:5 ratio,
and transgene expression was induced by 1 μg/ml doxy-
cycline (Dox; Sigma) for 24 h. Efficiencies of transfection
of > 70% were achieved.
Immunofluorescence
Cells were grown on poly-ornithine (3 μg/ml; Sigma)
and laminin (5 μg/ml; Invitrogen, Carlsbad, CA) coated
cover slips, washed once in PBS, and fixed in 3%
paraformaldehyde in phosphate buffer as described pre-
viously [28]. The percentage of pyknotic nuclei was
obtained by counting 20 random fields per sample at
40× as described [28], in each of 7-13 different cultures
from 3 independent isolations. To analyze the effects of
Ab42 on synapses, images were collected in a Leica TCS
SP5 Confocal Microscope (Leica Microsystems Inc.,
Bannockburn, IL) using a 63× lens, a standard pinhole
of 1, optical intervals of 0.5 μm, 16-bit depth resolution,
and with equal exposure times. MetaMorph software
(Universal Imaging, West Chester, PA) was used for
quantitative analysis. Threshold was set at least 2×
above background levels. To analyze synaptic density
(referred to as the number of synapses present in a
given neurite segment) at least 5 random fields were
imaged from each neuronal culture (3-5 different cul-
tures from 3 independent isolations).
Statistical analysis
Statistical significance was determined by the Student’s
two-tailed, unpaired t test, and a p value < 0.05 was
considered indicative of a significant difference. All bar
graphs are expressed as SEM.
Additional material
Additional file 1: “Ab expression in transgenic strains and dose-
response toxicity analysis for Ab oligomers in hippocampal
neurons.” This file contains measurements of relative Ab expression and
toxicity for all transgenic nematode strains used in this study (Table S1
and Figure S2) and quantification of drebrin expression in hippocampal
neurons exposed to different levels of Ab wild type or G37L oligomers.
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Aβ: β-amyloid peptide; N2a: Neuro2a; MTT: (3-(4,5-Dimethylthiazol-2-yl)-2,5-
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